Intuitive Surgical, Inc. (NASDAQ:ISRG) Position Trimmed by 2Xideas AG

2Xideas AG trimmed its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 16.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,472 shares of the medical equipment provider's stock after selling 2,778 shares during the quarter. 2Xideas AG's holdings in Intuitive Surgical were worth $7,554,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Alcosta Capital Management Inc. bought a new stake in Intuitive Surgical during the fourth quarter valued at $4,891,000. Waterloo Capital L.P. boosted its holdings in shares of Intuitive Surgical by 11.6% in the 4th quarter. Waterloo Capital L.P. now owns 4,865 shares of the medical equipment provider's stock valued at $2,539,000 after buying an additional 506 shares during the period. Peapack Gladstone Financial Corp grew its position in shares of Intuitive Surgical by 3.0% during the 4th quarter. Peapack Gladstone Financial Corp now owns 13,476 shares of the medical equipment provider's stock valued at $7,034,000 after buying an additional 391 shares during the last quarter. Quadrant Capital Group LLC raised its stake in Intuitive Surgical by 4.4% during the fourth quarter. Quadrant Capital Group LLC now owns 5,831 shares of the medical equipment provider's stock worth $3,044,000 after acquiring an additional 245 shares during the period. Finally, Russell Investments Group Ltd. lifted its holdings in Intuitive Surgical by 1.8% in the fourth quarter. Russell Investments Group Ltd. now owns 355,440 shares of the medical equipment provider's stock worth $185,622,000 after acquiring an additional 6,431 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Trading Up 0.4 %

Shares of NASDAQ ISRG traded up $2.14 during midday trading on Friday, reaching $491.66. The company's stock had a trading volume of 1,320,126 shares, compared to its average volume of 1,592,395. Intuitive Surgical, Inc. has a one year low of $364.17 and a one year high of $616.00. The company has a market cap of $175.12 billion, a price-to-earnings ratio of 76.00, a price-to-earnings-growth ratio of 5.85 and a beta of 1.55. The company has a 50 day moving average price of $534.44 and a 200 day moving average price of $532.30.

Insider Buying and Selling at Intuitive Surgical

In other news, Director Amal M. Johnson sold 4,635 shares of the business's stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the sale, the director now owns 12,275 shares in the company, valued at $6,955,015. The trade was a 27.41 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Robert Desantis sold 11,545 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $499.22, for a total transaction of $5,763,494.90. Following the completion of the sale, the executive vice president now owns 5,224 shares of the company's stock, valued at approximately $2,607,925.28. This trade represents a 68.85 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,754 shares of company stock valued at $17,691,621. Corporate insiders own 0.70% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Evercore ISI upped their target price on Intuitive Surgical from $490.00 to $530.00 in a report on Monday, January 27th. Truist Financial dropped their target price on Intuitive Surgical from $666.00 to $605.00 and set a "buy" rating on the stock in a research report on Monday, March 17th. UBS Group raised their target price on Intuitive Surgical from $500.00 to $560.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. Piper Sandler restated an "overweight" rating and set a $670.00 price target (up previously from $538.00) on shares of Intuitive Surgical in a research report on Friday, January 24th. Finally, Robert W. Baird cut their price objective on shares of Intuitive Surgical from $707.00 to $600.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $611.86.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.